April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Pharmacokinetic Modeling of Azithromycin in Rabbit Eyelids Following Topical Ocular Administration of AzaSite®
Author Affiliations & Notes
  • J. L. Vittitow
    Research & Preclinical Development, Inspire Pharmaceuticals Inc, Durham, North Carolina
  • A. J. Parham
    Research & Preclinical Development, Inspire Pharmaceuticals Inc, Durham, North Carolina
  • W. M. Bodnar
    Research & Preclinical Development, Inspire Pharmaceuticals Inc, Durham, North Carolina
  • C. S. Crean
    Research & Preclinical Development, Inspire Pharmaceuticals Inc, Durham, North Carolina
  • Footnotes
    Commercial Relationships  J.L. Vittitow, Inspire Pharmaceuticals, E; A.J. Parham, Inspire Pharmaceuticals, E; W.M. Bodnar, Inspire Pharmaceuticals, E; C.S. Crean, Inspire Pharmaceuticals, E.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2672. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. L. Vittitow, A. J. Parham, W. M. Bodnar, C. S. Crean; Pharmacokinetic Modeling of Azithromycin in Rabbit Eyelids Following Topical Ocular Administration of AzaSite®. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2672.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate and mathematically model the pharmacokinetics (PK) of a proprietary, polycarbophil-containing formulation of azithromycin (AZM) in rabbit eyelids following topical administration.

Methods: : Dutch-belted rabbits were instilled with 30 µL of AZM ophthalmic solution 1% to the right cornea. Drug was administered BID (0800 and 1700) on days 1 and 2 and QD (0800) on days 3-7. Eyelids were collected preinstillation, 0.5 and 1 h following the 0800 instillation on days 1-6 and at multiple time points for 16 days after the last instillation on day 7 (144 h after 1st administration). AZM levels were measured by LC/MS/MS and PK analysis was conducted with Winnonlin v5.2. A mathematical PK model was developed based on the above data and validated with a second study involving a different administration paradigm, where drug was instilled QD (0800) on days 1-7 and 15-21 and eyelids collected Qam (0800) on days 15, 22 and 30.

Results: : In the first dosing paradigm, peak eyelid concentrations increased over the course of administration with Cmax of 180.3 µg/g on Day 7. The AUC0-144h prior to the last administration was 8,926 µg*h/g, whereas the total observed AUC0-504h was 21,813 µg*h/g. AZM exhibited a terminal elimination half-life of 193 h. A 3-compartment model with 15 minute constant order drug input after each instillation was developed that demonstrated a 94.3% correlation between predicted and observed concentrations from the model development study. Predicted eyelid concentrations from the validation study were within the 90% confidence interval (CI) of the experimental data on Days 15 [28.4 µg/g, CI (28.4-40.6)], 22 [88.8 µg/g, CI (49.2-91.1)] and 30 [23.8 µg/g, CI (21.0-39.1)].

Keywords: eyelid • antibiotics/antifungals/antiparasitics • bacterial disease 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×